Trial site
Medizinische Studiengesellschaft NORD-WEST GmbH
Westerstede, 26655, GermanyNot linked to an institution yet
- 8running trials
- 2closed trials
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 42 trials
- Status
- Active, not recruiting4 trials
- Recruiting3 trials
- Completed2 trials
- Not yet recruiting1 trial
- Lead sponsor
- AIO-Studien-gGmbH1 trial
- BeOne Medicines1 trial
- BeOne Medicines I GmbH1 trial
- Institut Für Frauengesundheit GmbH1 trial
- Ipsen1 trial
- and 5 more
Running trials
Not yet recruiting
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
NCT07715396· Phase 3· AIO-Studien-gGmbH· Source
Recruiting
BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
NCT07492641· Phase 3· BeOne Medicines I GmbH· Source
Active, not recruiting
A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and safety of two dexamfetamine sulfate formulations in adults with ADHD - DEXINA -
2022-502903-31-00· Phase 3· Medice Arzneimittel Puetter GmbH & Co. KG· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS
NCT05452213· Phase 4· Institut Für Frauengesundheit GmbH· Source
Active, not recruiting
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
NCT04767594· Pfizer· Source
Active, not recruiting
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
NCT03647878· Ipsen· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error